In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Alnylam nets $784.9mm through public stock offering

Executive Summary

Alnylam Pharmaceuticals Inc. (RNAi therapeutics) netted $784.9mm through the public sale of 6.44mm common shares (including the overallotment) at $125. Proceeds will support future commercialization activities surrounding patisiran (for hereditary ATTR (hATTR) amyloidosis with symptomatic polyneuropathy (previously known as familial amyloidotic polyneuropathy (FAP)); givosiran (acute hepatic porphyrias); and fitusiran (moderate or severe hemophilia A or B).
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Synthesis Technologies, Production Processes
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies